Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, et al. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. J Clin Oncol 2022;40:932-944.
PMID: 34767461